Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Chemotherapy compounds affected chemosensitivity of cervical cancer cells
September 8th, 2005
Scientists suggested that after reactivating p53, varying chemotherapy compounds differentially affected the chemosensitivity of cervical cancer cells. According to a study from Finland, "Constant expression of E6 and E7 mRNA by high-risk human papillomaviruses (HPV) abrogates p53 and retinoblastoma protein function, respectively, and is essential for the development of cervical cancer. Despite E6, some chemotherapy drugs can stabilize p53 in cervical cancer cells. It is not known how chemotherapy-induced p53 activation and cytotoxicity are affected when the amount of E6 mRNA is decreased before the drug treatment." "In this study, HPV18-positive...
Source: Women's Health Weekly (2005-09-08)
|
